The American Board of Internal Medicine (ABIM) has ABIM has 12 Specialty Boards - one for all disciplines solely sponsored and administered by ABIM. The Specialty Boards are where the frontline work at the discipline-specific level is done.
Brexucabtagene autoleucel (TECARTUS, Kite, a Gilead Company) has been approved for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). This is the first chimeric antigen receptor (CAR) T cell therapy approved for MCL.
The Lymphoma Research Foundation (LRF) welcomes three new members to their elite Scientific Advisory Board (SAB). The new members represent distinct specialties that will contribute to the international impact of the Lymphoma Research Foundation.
Selinexor (XPOVIO, Karyopharm Therapeutics, Inc.) is a single-agent oral tablet approved for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma (FL), after at least 2 lines of systemic therapy.
Tazemetostat (TAZVERIK), an EZH2 inhibitor, and the EZH2 Mutation Test were granted approval for adult patients with relapsed or refractory follicular lymphoma (FL).
Dr. Kara Kelly is helping to build the bridge between AYA, and pediatric and adult oncology fields to bring attention to this underserved population and improve patient care.
Subscribe to Our Emails. Get lymphoma and CLL resources and updates.